After hours of tense debate, the Alabama Senate voted on Wednesday to pass a bill to legalize medical marijuana in the state.
Lawmakers voted 22-11 in support of the legislation, which would allow qualifying patients to purchase certain medical marijuana products from state-licensed dispensaries. Cannabis intended for smoking or vaping would be prohibited under the proposal, meaning only preparations such as tablets, topicals and certain infused edibles would be available.
“I think in this day and time, with the opioid crisis, we need to try alternative medicines that will help people,” said Sen. David Sessions (R), who voted to pass the bill.
With the Senate’s approval on Wednesday, the proposal now heads to the House, where its prospects are unclear. Speaker Mac McCutcheon (R) has been noncommittal, telling reporters last month that he was in “wait and see mode.”
The state’s attorney general, meanwhile, has urged lawmakers to oppose any move to legalize.
The bill, SB 165, would establish a state Medical Cannabis Commission to register patients and oversee licensing businesses.
Under the measure, patients suffering from specified conditions would qualify for the program. Those include anxiety, cancer, epilepsy and post-traumatic stress disorder (PTSD). Patients would be able to purchase up to a 70-day supply at a time, and there would be a cap of 32 dispensaries allowed in the state.
Products would be tested for potency and contaminants, and sales from licensed dispensaries would be subject to a nine percent tax. Part of those funds would go toward creating a new Consortium for Medical Cannabis Research, which would provide grants to study the plant.
Medical marijuana would be tracked from seed to sale under the measure, which also contains a number of restrictions on advertising. Workers at cannabis facilities would be subject to background checks.
“Today’s landslide vote in the Alabama Senate shows lawmakers in even the most conservative states in the nation are starting to recognize that allowing medical cannabis is good politics and good policy. Voters of every political background overwhelmingly support allowing medical cannabis,” Karen O’Keefe, state policies director for the Marijuana Policy Project, told Marijuana Moment. “That said, with polls showing upwards of 90 percent of Americans supporting allowing medical marijuana, it’s alarming that 27 states continue to criminalize patients for choosing a safer alternative to opioids.”
The bulk of opposition during Senate debate on Wednesday came from Sen. Arthur Orr (R). Orr, who admitted at times that he was unfamiliar with certain aspects of the bill as well as underlying research around medical marijuana generally, questioned virtually every element of the bill and its amendments.
At one point he demanded that Sen. Tim Melson (R), SB 165’s sponsor, produce medical literature in support of the legalization proposal. But Orr indicated that even such evidence wouldn’t change his mind: “What happened in the world of opioids, I don’t know that I really trust the medical community as a broad group,” he said.
Orr also attacked a successful amendment by Sen. Bobby Singleton (D) that would work to ensure diversity in the state’s new medical marijuana industry. When Orr complained that he wasn’t privy to what was in the proposal, Singleton replied: “You just told me you really didn’t get involved in it and didn’t look at it.”
In response to badgering from Orr, who described the relatively modest medical marijuana proposal as taking a “pedal to the metal” approach, Melton replied: “I’m beginning to wonder how long you left your training wheels on.”
The Senate also approved a raft of additional amendments to the bill during Wednesday’s debate. The most notable of the changes imposes a 75-milligram daily limit on THC intake, where previously the bill had no limit. (Orr proposed a lower, 50-mg limit, as well as a separate measure limiting cannabis products to 10 percent THC, but those amendments failed.) Another will prevent regulators from expanding the current list of qualifying conditions, instead requiring sign-off from lawmakers. Other approved changes will expand the number of available business licenses and restrict those licenses to in-state actors.
A measure to add menopause or premenstrual syndrome as qualifying medical conditions for cannabis was also approved after a brief delay in the chamber to consider other legislation.
Following the spurt of amendments, Orr threatened to kill the bill by speaking until midnight, especially if none of his amendments were accepted. He then introduced another proposal to remove some of the qualifying conditions but told members they were free to leave for the hour he was allotted to speak before coming back to vote. In effect, he was making good on his threat and engaging in somewhat of a filibuster to delay the legislation. That measure was defeated.
Another Orr amendment, which was approved, limits medical cannabis products for minors to 3 percent THC.
Those changes came in addition to other amendments added during a Senate Judiciary Committee hearing last month. One amendment approved by the panel shields doctors from legal liability for recommending marijuana, which remains illegal under federal law. Another clarifies that workers who cause accidents while under the influence of cannabis don’t qualify for workers’ compensation.
While Melson and supporters pushed back some of the restrictive changes proposed on the floor, they embraced others as likely to help build political support for the bill.
The Senate approved a separate medical marijuana bill last year, but it was ultimately gutted in the House. As enacted, the legislation did not include provisions to legalize cannabis but instead set up a study commission to look into the issue and develop recommendations.
In December, the newly created study commission came back with its report, which recommended medical marijuana be legalized.
“Although some medical study results are inconclusive and some results are mixed,” the report found, “there is strong scientific evidence that both hemp and marijuana contain compounds that provide significant relief for symptoms of certain specified medical conditions.”
Melson, the sponsor of both SB 165 and last year’s legalization bill, says the new measure is an updated and more politically feasible version of last year’s legislation that incorporates the study group’s recommendations.
Photo courtesy of Rick Proctor
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers